SCHEMBL12929596

SCHEMBL12929596

CCOC(=O)c1cnc(-c2ccc(C)cc2)nc1N(CC)CC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.65
SMN1; SMN2 Q16637 5/20 0.65
MAPT P10636 5/20 0.55
LMNA P02545 4/20 0.55
MAPK1 P28482 1/20 0.55
ATM Q13315 1/20 0.55
NPC1 O15118 3/20 0.54
RAB9A P51151 2/20 0.54
TP53 P04637 2/20 0.54
ALOX15 P16050 1/20 0.53
FOS P01100 4/20 0.53
JUN P05412 4/20 0.53
NFKB1 P19838 4/20 0.53
NFKB2 Q00653 4/20 0.53
RELA Q04206 4/20 0.53
HSD17B10 Q99714 1/20 0.52
CYP1A2 P05177 4/20 0.51
POLB P06746 2/20 0.51
CYP2C9 P11712 2/20 0.51
CYP2C19 P33261 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12929721 0.90 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL12929634 0.90 ALDH1A1 (0.80) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL12929583 0.89 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL12929724 0.83 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL11785304 0.82 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL12929723 0.81 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL12929612 0.80 ALDH1A1 (0.80) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL12929598 0.80 ALDH1A1 (0.80) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL12929579 0.80 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL12929679 0.80 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324220-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-04 US disclosed
US-8324220-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-04 US disclosed
US-20110003814-A1 PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-06 US disclosed
US-20110003814-A1 PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-06 US disclosed
US-7816529-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-19 US disclosed
US-7816529-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003814-A1 PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS KCNJ1, KCNJ11, TRPV1 ALDH1A1 2361/4885SMN1; SMN2 1190/4885MAPT 2103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.